Business Context and Reporting Period
Company: Personalis, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2025
Event: Entry into a Material Definitive Agreement (Amendment No. 4 to the Commercialization and Reference Laboratory Agreement with Tempus AI, Inc.).
Key Financial Metrics
This filing is a qualitative report regarding a contractual amendment. It does not contain quantitative financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial figures.
Material Changes Versus Prior Period
The filing details significant modifications to the existing agreement with Tempus AI, Inc. compared to the prior state of the contract:
- New Indication: Added colorectal cancer as a fourth indication for the marketing of the NeXT Personal® test, alongside existing indications for breast cancer, lung cancer, and immuno-oncology monitoring.
- Term Extension: Extended the agreement term through November 25, 2029.
- Exclusivity Expansion: Included colorectal cancer under the exclusivity provisions. The Exclusivity Period (during which Personalis cannot allow third parties to market NeXT Personal® and Tempus cannot market competing assays) is extended to December 31, 2028.
- Standstill Modification: Modified customary standstill restrictions to automatically expire on the earlier of June 4, 2027, or the expiration/termination of the Exclusivity Period.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the strategic expansion of the commercial partnership with Tempus to cover colorectal cancer, reinforcing the exclusivity arrangement for tumor-informed minimal residual disease testing.
Risks and Contingencies: The filing notes that the exclusivity and standstill provisions are subject to certain exceptions and may expire earlier if the agreement is terminated. No specific financial risks or forward-looking guidance regarding revenue impact were disclosed in this text.
Important Facts for Investor Verification
- Verify the specific commercial terms and royalty structures for the new colorectal cancer indication, as they are stated to be on the "same terms" as existing indications but details are not in this filing.
- Confirm the exact scope of the "certain exceptions" to the exclusivity and standstill provisions.
- Monitor future filings for financial impact analysis related to the expanded commercialization rights.
- Note the new expiration dates: Agreement term ends November 25, 2029; Exclusivity Period ends December 31, 2028; Standstill restrictions expire June 4, 2027 (or earlier).